Supply Chain Archives
10/08/2025
Resilience by Design: Lessons from Real-World Disruption
When it comes to Advanced Therapy Medicinal Products (ATMPs), disruption isn’t an “if,” it’s a “when.” When you’re dealing with unpredictable situations like geopolitical instability, sudden site closures, supply chain bottlenecks, or even weather-related delays, any disruption can potentially jeopardize patient treatments that may be irreplaceable. For sensitive therapies like these with narrow viability windows and strict temperature requirements, even a small deviation in process can have outsized consequences. In her Beyond Biotech podcast interview with Labiotech, Alison Pritchard, VP of Business Development for EMEA at Cryoport Systems, explained why resilience is one of the most critical (but often overlooked) pillars of ATMP delivery.
10/01/2025
Cryoport Systems Redefines the Global Supply Chain with Launch of New Facility Near Paris, France
Cryoport Systems is thrilled to announce the grand opening of our revolutionary Global Supply Chain Center in Louvre, France. This cutting-edge campus is a one-stop location for end-to-end, temperature-controlled supply chain solutions and is designed to tackle the most complex challenges in the life sciences industry.
09/15/2025
What’s Slowing the Journey from Therapy to Patient? Inside the Operational Hurdles of ATMPs
As more advanced therapy medicinal products (ATMPs) move from clinical trials to commercial launch, the industry has reached a critical inflection point. The science is advancing, approvals are accelerating, but patients still face steep barriers to access. In her Beyond Biotech podcast interview with Labiotech, Alison Pritchard, VP of Business Development for EMEA at Cryoport Systems, outlined the operational realities that stand between innovation and patient benefit. These challenges span manufacturing capacity, cold chain infrastructure, site coordination, and regional complexity.
09/10/2025
Scale Smarter: How Global Supply Chain Centers Amplify CGT Program Growth
Cell and gene therapy (CGT) programs are among the most complex and sensitive operations in the life sciences. From cryopreservation and biostorage to logistics and regulatory compliance, every step in the supply chain can influence product integrity, clinical timelines, and the scalability of the program. For program heads as well as clinical and technical operations teams, the challenge becomes bigger than merely moving materials. It quickly becomes a challenge of scaling efficiently while maintaining compliance and supporting growth across a global network.
08/29/2025
The Hidden Risks in Your Supply Chain: How Regulatory Support Can Save Your CGT Program
The temperature-controlled supply chain has become so much more than a straightforward logistics function, especially for advanced therapies. It has quickly evolved into a critical extension of your manufacturing process, your clinical trials, and your path to commercialization. Every step, from sourcing raw materials to delivering the final drug product to patients, must operate within strict regulatory and quality parameters where even the smallest oversight can cascade into regulatory delays, product loss, or even compromised patient safety.
08/25/2025
What’s Next for ATMP Regulation in EMEA
For advanced therapy developers expanding into Europe, regulatory approval is just the beginning. Even after securing authorization from the European Medicines Agency (EMA), companies often find themselves mired in a patchwork of national rules, pricing hurdles, and even access delays. In her recent appearance on the Beyond Biotech podcast by Labiotech, Alison Pritchard, Vice President of Business Development for Cryoport Systems in EMEA, pulled back the curtain on what it really takes to bring advanced therapies to patients across the region.
08/20/2025
Protecting the Foundation of Biologics with Flexible, Scalable Cell Banking
For any biotherapeutic program, your cell bank is the foundation of your manufacturing process. Master cell banks (MCBs), working cell banks (WCBs), and research cell banks (RCBs), represent years of development work and intellectual property. They are irreplaceable assets, and the security of these assets is directly tied to the long-term success of your program.
08/04/2025
ATMP Development in 2025: Promise, Pressure, and the Push to Scale
As the advanced therapy medicinal products (ATMP) sector reaches the midpoint of 2025, there’s no shortage of scientific momentum. Groundbreaking CRISPR-based therapies are making headlines. Patient access to cell and gene therapies is expanding beyond early adopter markets. And a maturing global regulatory environment is slowly but surely creating new opportunities for commercialization. But alongside this promise comes pressure.
08/01/2025
